GOVX GeoVax Labs, Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$2.21

Period return

-7.09 (-76.24%)

Volume

2.0M

2026-06-01O $2.3 H $2.39 L $2.13 C $2.21MA5 $2.57MA20 $2MA60 $1.59MA120 $2.7

6M · 124 barsYahoo Finance · USD2025-12-02 → 2026-06-01

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 04. 16.LowHOLD2 months ago
D. Boral Capital: Hold
US analyst rating / recommendation change.
2026. 02. 20.MediumHOLD3 months ago
D. Boral Capital: Hold
US analyst rating / recommendation change.
2026. 01. 21.LowBUY4 months ago
D. Boral Capital: Buy
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $10 · 2 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; and the U.S. Department of Defense. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.

Sector: Healthcare
Industry: Biotechnology
HQ: Smyrna, GA, United States
Fiscal year end: —

2025. 11. 19.LowBUY6 months ago

D. Boral Capital: Buy